RxDoctor Payments Data

Joannes Paul, MD

Neurology · Boca Raton, FLNPI 1336468198

Payments from drug & device makers

$8,158in general payments, 2019–2025

Across 449 payments — averaging $18.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Sanofi$612
  • AstraZeneca$591
  • Amgen$476
  • Lundbeck LLC$404
  • Teva Pharmaceuticals USA, Inc.$361
  • plus $5K from 51 others

What the payments were for

  • Speaking & faculty fees$1161%
  • Food & beverage$8,02598%
  • Education$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)80$1,012
Sanofi28$612
AstraZeneca(2 entities)28$591
Amgen(2 entities)22$476
Lundbeck LLC17$404
Teva Pharmaceuticals USA, Inc.22$361
Lilly USA, LLC20$337
UCB, Inc.15$329
Novartis23$314
Acadia Pharmaceuticals Inc30$298
EMD Serono, Inc.12$250
Takeda Pharmaceuticals U.S.A., Inc.9$238
Argenx US, Inc.9$228
Bristol Myers Squibb12$219
Johnson & Johnson13$183
Pfizer8$173
Genentech USA, Inc.6$154
MDD US Operations, LLC8$153
Merz Pharmaceuticals, LLC7$153
CSL Behring4$111
Merz North America, Inc.5$108
Biohaven Pharmaceuticals, Inc.6$102
Acorda Therapeutics, Inc5$96
Avion Pharmaceuticals5$86
Neurocrine Biosciences, Inc.4$84
Catalyst Pharmaceuticals, Inc.1$64
Vanda Pharmaceuticals Inc.3$62
Kyowa Kirin, Inc.3$58
Greenwich Biosciences, Inc.3$53
Grifols USA, LLC3$52
Insightec,inc2$50
SK Life Science, Inc.2$49
Mallinckrodt Hospital Products Inc.2$48
Biohaven Pharmaceutical Holding Company Ltd.3$46
Arbor Pharmaceuticals, Inc.2$44
Tanabe Pharma America, Inc.2$41
Harmony Biosciences LLC1$40
C2n Diagnostics, LLC2$40
Supernus Pharmaceuticals, Inc.2$36
Adamas Pharmaceuticals, Inc.2$36
Impel Pharmaceuticals Inc.2$33
Vertical Pharmaceuticals, LLC1$33
Revance Therapeutics, Inc.1$28
Almatica Pharma LLC1$27
Mallinckrodt Enterprises LLC1$27
E.r. Squibb & Sons, L.L.C.1$26
Scilex Pharmaceuticals Inc.1$24
Abbott1$20
Eisai Inc.1$20
Biogen1$20
Nevro Corp.1$18
Alnylam Pharmaceuticals Inc.1$17
Neurelis, Inc.1$17
Xeris Pharmaceuticals, Inc.1$15
Amneal Pharmaceuticals LLC1$15
Aucta Pharmaceuticals, Inc.1$13
Avanir Pharmaceuticals, Inc.1$13

How this compares

$8,158 in reported general payments places this provider in the 60th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$354,529
Medicare patients
988
Services billed
3,281

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5012$201,996
NuplazidPimavanserin Tartrate18$160,698
BotoxOnabotulinumtoxina82$115,477
Gamunex-CImmune Globul G/Gly/Iga Avg 4616$106,051
Avonex (4 Pack)Interferon Beta-1a11$105,471
AustedoDeutetrabenazine18$98,695
Aimovig AutoinjectorErenumab-Aooe49$46,468
NeuproRotigotine21$22,976
Emgality PenGalcanezumab-Gnlm20$16,092
Memantine Hcl346$14,348
QuliptaAtogepant12$12,721
Galantamine ErGalantamine Hbr139$9,229
XeominIncobotulinumtoxina13$7,502
Rivastigmine65$6,349
Aripiprazole12$5,248

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$238$201,99612 claims
Acadia Pharmaceuticals IncNuplazid$298$160,69818 claims
AbbVieBotox, Qulipta$1,012$128,19894 claims
Grifols USA, LLCGamunex-C$52$106,05116 claims
BiogenAvonex (4 Pack)$20$105,47111 claims
Teva Pharmaceuticals USA, Inc.Austedo$361$98,69518 claims
UCB, Inc.Neupro$329$22,97621 claims
Merz North America, Inc.Xeomin$108$7,50213 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$15$1,06617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,434 neurology providers in Florida.

Other neurology in Boca Raton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →